Experimental data in humans also indicated that the addition of GLP‐1RAs to insulin in normal‐weight T1D patients with detectable beta‐cell reserve is associated with glucose control improvement, reduces insulin requirement, stimulates endogenous insulin secretion (as expressed by a 3.5‐fold increase in serum c‐peptide concentration) and autonomy from insulin therapy in 5 of 11 patients treated over a period of 12 weeks [27]. This evidence concerns the gene INS and type 1 diabetes mellitus.